Global network connection. World map point and line composition concept of global business. Internet technology. Social network
Credit: AliseFox/Getty Images

Sponsored content brought to you by

BC Platforms logo


Real-world data (RWD) is enabling clinical trial research to better represent “real-world” scenarios and allowing the use of data beyond randomized clinical trials, including virtual patient cohorts. Generated by routine, patient standard-of-care, RWD captures information about comorbidities, disease complexity, patient paths, and outcomes in real-world settings.

RWD is increasingly a source of assurance for drug development to be accepted by decision-makers and adopted in medical practice, alongside gold-standard clinical trial efficacy and safety data together with genomic data. With such vast potential, finding the right data for the right purpose is essential to capitalize on RWD’s promise—promoting safe and secure data sharing across borders, while also maintaining trust and transparency. Access to volumes of data alone is not enough. Those wishing to unlock RWD’s true value must have a variety of high-quality data sources or types, in addition to technological capabilities that can efficiently uncover meaningful insights.

Drug development teams are often stretched to support the rigorous demands that global patient data sourcing and analytics requires. To address this need, BC Platforms has leveraged its technical expertise to offer robust and comprehensive solutions that maximize RWD return-on-investment.

BC Platforms’ latest release—BC|RQUEST

With the most recent release of BC|RQUEST, a Software as a Service (SaaS) environment, BC Platforms’ global federated clinical and genomic network delivers groundbreaking software that revolutionizes drug development and discovery. It offers valuable insights and breakthroughs tailored to diverse patient populations, delivered through advanced visualization tools, detailed demographics distribution, and code distribution statistics.

BC|RQUEST enables secure and compliant access to clinical data, significantly enhancing the speed and effectiveness of clinical trials—including an unprecedented and extensive patient reach of over 70 million patients. Of this RWD catchment, most of it is available for querying directly from the BC|RQUEST system. The new release presents a major step forward in accelerating the role of RWD—reducing overall costs for clinical trials through BC Platforms’ cutting-edge RWD network.

Why use BC|RQUEST?

Secure Trusted Research Environment: Operating within a trusted research environment, BC|RQUEST ensures strict compliance with GDPR and HIPAA regulations. The software guarantees secure data processing and analysis, facilitating seamless collaboration between biobanks and external researchers.

Accelerated Clinical Trials: By streamlining operations, BC|RQUEST expedites the clinical trial process, leading to faster approvals and improved patient outcomes. The software optimizes efficiency and enhances the overall success rate of clinical trials.

Efficient Data Request and Approval: BC|RQUEST offers a user-friendly interface that serves as a comprehensive portal for data requests and approvals, including an unprecedented, federated search ability across diverse geographies. Researchers can utilize the cohort search function to discover relevant data based on specific inclusion and exclusion criteria. Once approved, users gain access to the requested data through BC Platforms’ Trusted Collaboration Environment.

Bringing over 25 years of experience and demonstrated success in research scoping and planning, BC Platforms places the patient at the center of care. Its expertise in data analysis ensures rapid turnaround, quickly getting teams the insights needed for informed decision making. By delivering safe and secure data access and infrastructure, including BC|RQUEST, BC Platforms is helping address unmet medical needs and reducing the global patient burden on healthcare systems everywhere.


1. Subbiah, V. The next generation of evidence-based medicine. Nat Med 29, 49–58 (2023).


Find out more about BC Platforms:

Also of Interest